99.9% Pure Nootropic Powder Tianeptine Sodium Salt CAS 30123-17-2

Name: 99.9% Pure Nootropic Powder Tianeptine Sodium Salt CAS 30123-17-2
Brand: Qingdao Little Fox Biological and Technology Co., Ltd.
SKU: 1915938072

Shandong, ChinaQingdao Little Fox Biological and Technology Co., Ltd.

US$1.20-2.50

1 gram

Product profile

Powder

Yes

Customized

Non-Customized

Certification

GMP, USP, BP

Model NO.

Little Fox

Suitable for

Adult

State

Powder

Purity

>99%

Product Name

Tianeptine Sodium Salt

Storage

Cool Dry Place

Mf

C21h24cln2nao4s

Other Names

Tianeptine Sodium Salt

Packing

Foil Bag or as Customer Request

COA

Available

Sample

Available

Shelf Life

2 Years

Appearance

White Powder

Test Method

HPLC UV

Grade

Pharmaceutical Grade

MW

458.93

Application

Medicine Grade

CAS

30123-17-2

Function

Tianeptine Sodium Salt

Transport Package

Aluminum Foil Bag or as Your Requirement

Specification

25kg kraft bag or fiber drum

Trademark

Little Fox

Origin

China

HS Code

2935900090

Production Capacity

100000

Company profile

Qingdao Little Fox Biological and Technology Co., Ltd.

Shandong, China

Business Type: Manufacturer/Factory, Trading CompanyExport Year: 2016-09-28Nearest Port: QingdaoAverage Response Time: ≤2.31hTerms of Payment: LC, T/T, D/P, etc.International Commercial Terms(Incoterms): FOB, EXW, CIF, DDP, DAP

AI-Powered supplier vetting

SummaryThe supplier is a trading company focused on chemical products, primarily offering customization based on samples without any significant innovation capability or R&D focus. Their after-sales services lack formal procedures, and they do not participate in offline trade shows or maintain overseas warehouses. Financial data is consistently reported over the past three years, but there's no information on certification holdings or customer cases.

Supplier typeThe supplier is a trading company with a focus on chemical products, excluding hazardous chemicals. It operates as a Limited Company and is involved in the production and wholesale of chemical and pharmaceutical intermediates.

After-Sales capabilityThe supplier lacks formal written procedures or records for after-sales service capabilities, including handling customer complaints, which indicates a lack of structured after-sales service processes.

Financial creditThe supplier has consistently reported financial data over the past three years, indicating a stable financial record.

R&D capabilityThe supplier does not engage in R&D activities for new products, ODM services, or provide SDKs, suggesting limited innovation capability.

Customization capabilityThe supplier offers customization services based on samples, indicating an ability to tailor products according to specific client requirements.